ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated CLL

Slideset

Download these slides from our ASH 2020 live satellite symposium on CLL to review the most current clinical data on treating patients with relapsed/refractory CLL.

Released: December 04, 2020

Expiration: December 03, 2021

Share

Faculty

Brian T. Hill

Brian T. Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca Pharmacyclics AbbVie

Janssen administered by Scientific Affairs

Lilly

Faculty Disclosure

Primary Author

Brian T. Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Brian Hill, MD, PhD, has disclosed that he has received consulting fees and funds for research support from AbbVie, AstraZeneca, BeiGene, Genentech, and Pharmacyclics.